Home › Trials › NCT03605771

Observational study on advanced melanoma in Spain

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Observational Grupo Español Multidisciplinar de Melanoma · NCT03605771

This study looks at the medical records of people in Spain who were diagnosed with advanced melanoma since 2018 to learn more about how the disease affects them.

Quick facts

Study typeObservational
Enrollment400 (estimated)
Ages18 Years and up
SexAll
SponsorGrupo Español Multidisciplinar de Melanoma Academic / other
Locations39 sites (Alcoy, Alicante and 38 other locations)
Trial IDNCT03605771 on ClinicalTrials.gov

What this trial studies

This observational, multicentre epidemiological study aims to gather data from medical records of patients diagnosed with advanced metastatic or unresectable melanoma. The study focuses on patients who were first diagnosed with these conditions after January 8, 2018. By analyzing this longitudinal cohort, researchers hope to better understand the characteristics and progression of advanced melanoma in the Spanish population.

Who should consider this trial

Good fit: Ideal candidates for this study are patients of legal age with stage III, metastatic, or unresectable melanoma diagnosed after January 8, 2018.

Not a fit: Patients with localized melanoma or those diagnosed before January 8, 2018, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the characteristics of advanced melanoma, potentially leading to improved treatment strategies.

How similar studies have performed: While this study is observational and focuses on a specific population, similar studies have provided valuable epidemiological data in the past, suggesting potential for meaningful insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as: a. Disease onset as metastatic or unresectable disease; b. First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period.
* Signing the Informed Consent Form (ICF).
* A patient may have received the first or subsequent treatments for metastatic or unresectable disease in a hospital other than the centre where the ICF was signed, as long as the patient meets the inclusion criteria 1.
* A patient can only sign one ICF (cannot sign an ICF in two different centres).
* If a patient signs the ICF in a centre during the first-line therapy and then goes to another centre with consideration for the following lines: If the centre is associated with the GEM-1801 study, researchers will do their best to update the following lines and the patient status, introducing the new information in the centre where the ICF was initially signed. This information will be provided by the patient before contacting the principal investigator and always with prior consent of the patient, who will have previously provided the consent to contact by telephone for this purpose. If this second (or subsequent) centre is not associated with the GEM- 1801 study, this will be considered loss of follow-up, unless the patient returns to the GEM-1801 start centre, wherein the reporting physicians will do their best to update the information from other centres, always with prior patient consent, who will have previously signed the ICF; c) A patient card with the assigned code will be delivered.

Exclusion Criteria:

* Any patient not complying with inclusion criteria.

Where this trial is running

Alcoy, Alicante and 38 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Melanoma Stage IvMelanoma Stage IiiAdvanced Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.